Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab plus chemotherapy followed by avelumab + talazoparib maintenance versus chemotherapy + bevacizumab in first-line advanced ovarian cancer
2017-004456-30Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of avelumab, talazoparib and bevacizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Pfizer. Primary endpoint: Progression-Free Survival. Started Jun 2018; status: terminated.
02
Drugs
avelumabtalazoparibbevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2017-004456-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004456-30.